Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.

被引：1
作者：
Zimmer, Lisa
Eigentler, Thomas K.
Vaubel, Julia-Marianne
Mohr, Peter
Jradi, Zeinab
Kiecker, Felix
Utikal, Jochen
Berking, Carola
Kaempgen, Eckhart
Hauschild, Axel
Dippel, Edgar
Rompel, Rainer
Fluck, Michael
Stadler, Rudolf
Herbst, Rudolf
Terheyden, Patrick
Garbe, Claus
Loquai, Carmen
Schadendorf, Dirk
机构：
[1] Univ Duisburg Essen, Univ Hosp, Dept Dermatol, Essen, Germany
[2] Univ Tubingen, Dept Dermatol, Tubingen, Germany
[3] Elbekliniken, Dermatol Zentrum, Buxtehude, Germany
[4] Charite Campus Mitte, Univ Dept Dermatol, Berlin, Germany
[5] German Canc Res Ctr, Skin Canc Unit, Heidelberg, Germany
[6] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, Mannheim, Germany
[7] Univ Munich LMU, Dept Dermatol, Munich, Germany
[8] Univ Hosp, Dept Dermatol, Erlangen, Germany
[9] Univ Hosp Schleswig Holstein, Kiel, Germany
[10] Dept Dermatol, Ludwigshafen, Germany
[11] Dept Dermatol, Kassel, Germany
[12] Dept Dermatol, Munster, Germany
[13] Dept Dermatol, Minden, Germany
[14] Dept Dermatol, Erfurt, Germany
[15] Univ Hosp UKSH, Dept Dermatol, Lubeck, Germany
[16] Univ Tubingen Hosp, Dept Dermatol, Tubingen, Germany
[17] Univ Dept Dermatol, Mainz, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.9031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9031
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
    Okada, Morihito
    Kijima, Takashi
    Aoe, Keisuke
    Kato, Terufumi
    Fujimoto, Nobukazu
    Nakagawa, Kazuhiko
    Takeda, Yuichiro
    Hida, Toyoaki
    Kanai, Kuninobu
    Imamura, Fumio
    Oizumi, Satoshi
    Takahashi, Toshiaki
    Takenoyama, Mitsuhiro
    Tanaka, Hiroshi
    Hirano, Jun
    Namba, Yoshinobu
    Ohe, Yuichiro
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (18) : 5485 - 5492
  • [32] Efficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
    Cai, Z.
    Zhang, B.
    Yin, Y.
    Cao, D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 698 - 698
  • [33] An Open-Label, Multicenter,Single-Arm, Phase I Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of XNW5004 in Patients with Relapsed or Refractory Hematologic Malignancies
    Zheng Weiwei
    Zhou Hui
    Xi Zhang
    Jing Hongmei
    Zhou Dongmei
    Zhou Fang
    Gao Li
    Wan Wei
    Song Yaobo
    Yan, Haung
    Xu Linfeng
    Hu Yonghan
    Le Meijie
    Qi Junyuan
    Qiu, Lugui
    [J]. BLOOD, 2022, 140 : 9353 - 9355
  • [34] A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Espinosa, Enrique
    Haanen, John B. A. G.
    Hermann, Frank
    Nathan, Paul D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial
    Chen, Yuxi
    Pan, Yuan
    Xie, Yanyan
    Shi, Yuxun
    Lu, Yao
    Xia, Yiwen
    Su, Wenru
    Chen, Xiaoqing
    Li, Zuoyi
    Wang, Minzhen
    Miao, Siyu
    Yang, Yating
    Jin, Chenjin
    Luo, Guangwei
    Long, Shixian
    Xiao, Hui
    Huang, Chuangxin
    Zhang, Jian
    Liang, Dan
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [36] EFFICACY AND SAFETY OF ZIMBERELIMAB (GLS-010) MONOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II STUDY
    Wu, Xiaohua
    Xia, Lingfang
    Wang, Jing
    Wang, Chunyan
    Zhang, Qingming
    Zhu, Jianqing
    Rao, Qunxian
    Cheng, Huijun
    Liu, Zheng
    Yin, Yongmei
    Ai, Xiaohong
    Gulina, Kurban
    Zheng, Hong
    Luo, Xiaoyong
    Chang, Baoping
    Li, Li
    Liu, Haiyan
    Li, Yunxia
    Lou, Ge
    Zhou, Qi
    Zhu, Yanling
    Xiao, Zemin
    Tong, Jiandong
    Wang, Ke
    Chen, Jie
    Wang, Xia
    Song, Lijie
    Wei, Zhixia
    Ye, Yijing
    Zhu, Jiman
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A703 - A703
  • [37] Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study
    Wu, X.
    Xia, L.
    Wang, J.
    Wang, C.
    Zhang, Q.
    Zhu, J.
    Rao, Q.
    Cheng, H.
    Liu, Z.
    Yin, Y.
    Ai, X.
    Gulina, K.
    Zheng, H.
    Luo, X.
    Chang, B.
    Li, L.
    Liu, H.
    Li, Y.
    Zhu, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1506 - S1506
  • [38] Efficacy and safety of JMT103 in patients with giant cell tumor of bone: A multicenter, single-arm, open-label, phase Ib/II study.
    Niu, Xiaohui
    Wei, Feng
    Tu, Chongqi
    Huang, Gang
    Bi, Wenzhi
    Li, Jianmin
    Yao, Weitao
    Zhang, Xiaojing
    Shen, Jingnan
    Zhang, Guochuan
    Yan, Wangjun
    Yang, Jilong
    Lin, Jianhua
    Ye, Zhaoming
    Wang, Dong
    Guo, Zheng
    Tong, Zhichao
    Zhou, Yuhong
    Xu, Hairong
    Li, Tao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] A multicenter, open-label, single-arm, phase IV study evaluating the safety of biosimilar bevacizumab in patients with solid tumors
    Narayanan, P.
    Upveja, K. H.
    Deodhar, S.
    Kapur, R.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S1613 - S1613
  • [40] Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study
    Li Yanwei
    Feng, He
    Ren, Peng
    Yue, Jie
    Zhang, Wencheng
    Tang, Peng
    Shang, Xiaobin
    Pang, Qingsong
    Liu, Dongying
    Chen, Chuangui
    Pan, Zhanyu
    Tao, Yu Zhen
    [J]. ONCOLOGIST, 2020, 25 (10) : E1464 - E1472
12345